National Trends in The Treatment of Adult Diffuse Midline Gliomas: A Rare Clinical Scenario

Author:

Desai Jay1,Rajkumar Sujay1,Shepard Matthew2,Herbst John3,Karlovits Stephen4,Hasan Shakir5,Horne Zachary4,Wegner Rodney4

Affiliation:

1. Drexel University College of Medicine

2. Allegheny Health Network, Department of Neurosurgery

3. Allegheny Health Network Cancer Institute, Division of Medical Oncology

4. Allegheny Health Network Cancer Institute, Division of Radiation Oncology

5. New York Proton Center

Abstract

Abstract

Purpose: Diffuse midline gliomas (DMG) include all gliomas with a diffuse growth pattern occurring in midline structures of the brainstem. These tumors are classified as World Health Organization grade 4 with a mean survival between 9 and 19 months following diagnosis. There is currently no standard of care for DMG, and palliative radiation therapy has been proven to only extend survival by months. Our current study aims to report current treatment trends and predictors of the overall survival of DMG. Methods: We searched the National Cancer Database for adult patients treated for DMG from 2004 through 2020. Patients were required to have been treated with primary radiation directed at the brain with or without concurrent chemotherapy. Univariable and multivariable Cox regressions were used to determine predictors of overall survival. Results: Of the 131 patients meeting the inclusion criteria, 113 (86%) received radiation and chemotherapy. Based on multivariable Cox regression, significant predictors of survival were Charlson-Deyo comorbidity index and race. Patients with a Charlson-Deyo score of 1 had 2.72 times higher odds of mortality than those with a score of 0. Patients not identifying as White or Black had 2.67 times higher odds of mortality than those identifying as White. The median survival for all patients was 19 months. Conclusions: Despite being considered ineffective, chemotherapy is still administered in most adult patients diagnosed with DMG. Significant predictors of survival were Charlson-Deyo comorbidity index and race.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3